Disease characteristics and demographic data of patients, divided by response to vedolizumab
| Responders to VDZ, n=8 | Non-responders to VDZ, n=20 | P values, IBD | |
| Gender (male/female) | 2/6 | 10/10 | P=0.23∆ |
| UC: 2/2 | UC: 8/5 | UC: P=0.68 | |
| CD: 0/4 | CD: 2/5 | CD: P=0.24 | |
| Age (median, range) | 42 (23–59) | 39 (18–62) | P=0.85ᵒ |
| UC: 34 (23-44) | UC: 42 (27-62) | UC: P=0.16 | |
| CD: 49 (32-59) | CD: 30 (18-53) | CD: P<0.05 | |
| Disease score prior to VDZ initiation (median, range) | – | – | – ᵒ |
| UC: Mayo score | UC: 8 (6 – 12) | UC: 6 (4–9) | UC: P=0.15 |
| CD: HBI score | CD: 8 (7–9) | CD: 11 (10-16) | CD: P<0.01 |
| Disease duration, years (median, range) | 17 (7–41) | 7 (1–17) | P<0.05ᵒ |
| UC: 8 (7–25) | UC: 5 (1–16) | UC: P=0.11 | |
| CD: 22 (12-41) | CD: 12 (5-17) | CD: P=0.058 | |
| Current or past smoking (yes/no) | 2/6 | 5/15 | P=0.99 ∆ |
| UC: 2/2 | UC: 5/8 | UC: P=0.68 | |
| CD: 0/4 | CD: 0/7 | CD: P=ND | |
| CRP, mg/L (median, range) | 0 (0–4) | 3.5 (0–107) | P<0.05 ᵒ |
| UC: 0 (0–3) | UC: 3 (0–17) | UC: P=0.40 | |
| CD: 0 (0–4) | CD: 15 (4-107) | CD: P<0.01 | |
| Concurrent systemic steroid treatment (yes/no) | 1/7 | 5/15 | P=0.47 ∆ |
| UC: 1/3 | UC: 5/8 | UC: P=0.62 | |
| CD: 0/4 | CD: 0/7 | CD: P=ND | |
| Concomitant therapy; 5-ASA, thiopurine or methotrexate (yes/no) | 4/3 | 5/15 | P=0.12 ∆ |
| UC: 3/1 | UC: 12/1 | UC: P=0.35 | |
| CD: 1/3 | CD: 4/3 | CD: P=0.30 | |
| Previous surgery (partial resection, colonic or ileocecal) (yes/no) | 1/7 | 4/16 | P=0.64 ∆ |
| UC: 0/4 | UC: 0/13 | UC: P=ND | |
| CD: 1/3 | CD: 4/3 | CD: P=0.30 | |
| Intestinal disease location | UC: P=0.70∆ | ||
| CD: P=0.91 | |||
| UC/Proctitis | 2 | 5 | – |
| UC/Left-sided colitis | 0 | 2 | – |
| UC/Pancolitis | 2 | 6 | – |
| CD/Colon only | 2 | 4 | – |
| CD/Ileocolonic | 1 | 2 | – |
| CD/Ileum only | 1 | 1 | – |
∆χ2 square test.
ᵒMann-Whitney U test.
5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; CRP, C reactive protein; ND, cannot be calculated; UC, ulcerative colitis; VDZ: vedolizumab.